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Background: Cholinergic urticaria is uncommon and accounts for
10% of all young adults. To date, there is no effective therapy for
cholinergic urticaria.
Objective: To determine the therapeutic efﬁcacy of different drug
combinations in the treatment of cholinergic urticaria.
Patients and Methods: The participants included in the study are in
the age range of 16 to 29 years, with cholinergic urticaria of any
duration as diagnosed by physicians. Patients were recruited from
Asthma and Allergy Centers in Baghdad and Tikrit. The selected
patients were divided randomly into 3 groups according to the
treatment protocol. All patients completed screening before treatment.
Results: The study indicated that cholinergic urticaria was com-
pletely controlled in 30.4% of patients (group A) receiving 4 mg of
chlorpheniramine maleate, half hour before the exercise, plus
chlordiazopoxide (5 mg) and clindium bromide (2.5 mg) tablets, 3
times daily. However, cure rate was higher (83.1%) in patients
(group B) receiving 4 mg of chlorpheniramine maleate (histadine), 3
times daily, plus 25 mg of maprotiline HCl (ludiomil), once daily at
night. Furthermore, the complete cure rate was 85.4% in patients
(group C) receiving 4 mg of chlorpheniramine maleate (histadine)3
times daily, plus 200 mg of cimetidine (tagadine), 3 times daily. The
frequency of relapse was higher in group A (89%) as compared with
group B (68.4%) and group C (23.5%) (P , 0.0001).
Conclusions: Combination of H1 and H2 antagonists was more
effective based on complete control of cholinergic urticaria with lower
relapsing rate. However, a future placebo-controlled clinical trial taking
in consideration higher H1 antagonists than we used is warranted.
Key Words: cholinergic urticaria, antihistamines, cimetidine, map-
rotiline HCl, chlorodiazopoxide, clindium bromide
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Cholinergic urticaria is a very distinctive type of urticaria,in which characteristic small weal or/and itching occur.
The prevalence of cholinergic urticaria is variable. Moore-
Robinson and Warin1 found that about 0.2% of patients in
an outpatient dermatologic clinic had cholinergic urticaria.
However, many published series have found cholinergic urti-
caria to be common. The prevalence of cholinergic urticaria is
deﬁnitely higher in persons with urticaria; cholinergic urticaria
affected 11% of a population with chronic urticaria in one
study and 5.1% of persons with urticaria in another study.2,3
Cholinergic urticaria is one of the physical urticaria
brought on by a physical stimulus. Although the physical
stimulus that triggers the cholinergic urticaria might be consid-
ered to be the heat, the actual precipitating factor is sweating.
The deﬁnition and diagnostic testing of cholinergic urticaria has
been the subject of consensus panel recommendations.4
Mast cells seem to be critically involved in cholinergic
urticaria.5 Serum histamine, the principal mediator, rises in
concentration with experimentally induced exercise, accom-
panied by eosinophil and neutrophil chemotactic factors and
tryptase. A reduction of the alpha-1-antichymotripsin level, as
seen in some other forms of urticaria, is present, and the erup-
tion is improved with danazol. These ﬁndings have prompted
some to argue for protease role in histamine release.6
Although mast cells’ release seems to be involved in
cholinergic urticaria, less eosinophilic major basic protein is
present than that in many other forms of urticaria.3 The prev-
alence of cholinergic urticaria is variable, with a range from
0.2 to 11%.1 Cholinergic urticaria occurs in both men and
women, but it seems to be more common in men than in
women, and occurrence usually begins in people aged 10 to
30 years, with an average age at onset of 16 years.7–10
In cholinergic urticaria, the treatment goal is to ensure
rapid and prolonged control of symptoms and a rapid return to
normal social activities. Nonsedating H1 receptor antagonists,
such as cetirizine, are the primary treatment modality. UV
light has been beneﬁcial in some patients with cholinergic
urticaria, but there are contraindications to UV light. Ketofen
may be helpful in patients with both cold urticaria and
cholinergic urticaria. Danazol11,12 and beta-blockers, such as
propranolol, have been reported to be useful in cholinergic
urticaria.13 Benzoyl scopolamine administered topically and
scopolamine butylbromide administered orally may be help-
ful in blocking the appearance of cholinergic urticaria lesions
after challenge.14 The traditional options are antihistamines,
leukotriene inhibitors, and immunosuppressive agents.15
Rapid sweat desensitization with autologous sweat has been
reported in patients resistant to conventional therapy who
have sweat hypersensitivity.16 Whatever the treatment
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approach,13–19 however, in some patients, cholinergic urti-
caria may be refractory. The aim of this study was to deter-
mine the therapeutic efﬁcacy of different drug combinations
in the treatment of cholinergic urticaria.
PATIENTS AND METHODS
Study Population
The participants included in the study are with age
range of 16 to 29 years, with cholinergic urticaria of any
duration as diagnosed by physicians (allergologist). Patients
were recruited from patients attending Asthma and Allergy
Centers in Baghdad and Tikrit. The selected patients were
divided randomly into 3 groups according to the treatment
protocol. All patients completed screening before treatment.
Exclusion criteria are as follows:
1. Cholinergic urticaria associated to some underlying dis-
ease (Hodgkin lymphoma/vasculitis/lupus erythematosus/
hepatitis).
2. Patients under any systemic or topical medication for
cholinergic urticaria and/or an inferior washout period
as stated below:
• H1 antagonists, such as fexofenadine (5 days before
day 0), loratadine, desloratadine, cetirizine, hydroxy-
zine, diphenhydramine, cyproheptadine, etc (3 days
before day 0)
• H2 receptor antagonists, such as cimetidine, rani-
tidine, famotidine, etc (2 days before day 0).
• H1 and H2 receptor antagonists, such as doxepin
(7 days before day 0).
• Leukotriene antagonists, such as zaﬁrlukast, mon-
telukast, etc (4 days before day 0).
• Corticosteroids, such as prednisone, methylpred-
nisolone, etc (28 days before day 0).
• Tricyclic antidepressants, such as imipramine,
amitriptiline, etc (30 days before day 0).
3. Patients with analytical values twice as high than the
upper limit of normality in the following parameters:
alkaline aminotransferase, aspartate aminotransferase,
gama-glutamyl transferase, creatine kinase, and creati-
nine; and 1.5 times higher than the upper limit of nor-
mality for CK.
4. Other forms of urticaria.
5. Patients taking medications that are known to interact
with CYP3A4 isozyme of cytochrome: amiodarone,
carbamazepine, cyclosporine, terfenadine, glucocorti-
coids, phenytoin, rifampicin, macrolides (eg, erythro-
mycin, clarythromycine) and antifungal medications
(eg, ketoconazole, miconazole, ﬂuconazole), as well
as grapefruit juice.
6. Pregnant or lactating female.
Sufﬁcient washout time was required for previous
urticarial treatments (especially long-acting antihistamines
and corticosteroids) before the study drugs were administered.
Approval for the study was obtained from the Ethical
Committee, and all patients gave their informed consent.
The target population was 300 patients, 100 in each treatment
group. However, 8 patients defaulted from group A, 23 from
group B, and 18 from group C.
Study Design
The recruited patients were randomized to receive one
of the treatments listed below.
Group A
Group A includes 92 patients with age range of 16 to
29 years; they received 4 mg of chlorpheniramine maleate
(histadine), half an hour before the exercise challenge, plus
5 mg of chlordiazopoxide and 2.5 mg of clindium bromide
(librax), 3 times daily.
Group B
Group B includes 77 patients with age range of 17 to
27 years; they received 4 mg of chlorpheniramine maleate
(histadine), 3 times daily, plus 25 mg of maprotiline HCl
(ludiomil), once daily at night.
Group C
Group C includes 82 patients with age range of 19 to
29 years; they received 4 mg of chlorpheniramine maleate
(histadine), 3 times daily, plus 200 mg of cimetidine (taga-
dine), 3 times daily.
The treatment course lasted for 6 weeks. The study
comprised of 4 visits, initial and 3 follow-up visits every 2
weeks. Each patient was examined by the physician 4 times
over the 6-week period. The tablets were encapsulated in a
double blind fashion and sealed in envelop by a pharmacist
along with the instructions sheet at the beginning of the trial.
All treatments were dispensed by a third party. Medications
that could interfere with the clinical evaluations and systemic
or topical medication for urticaria, other than those speciﬁed
in the study treatment, were not allowed during the trial.
Informed patient consent was obtained before enrollment in
the study.
Patient Evaluation
Baseline assessment was performed at the beginning of
the study to measure the clinical condition through complete
history and physical examination. In addition, background
information on personal characteristics and clinical history was
also collected and family history of atopy was also recorded.
Blood samples were obtained from each patient to determine
white blood cell count (total and differential), packed cell
volume, erythrocyte sedimentation rate, and serological test
(lupus erythematosus test and Rh factor). Complete cure is
deﬁned as absence of signs and symptoms, whereas relapse is
deﬁned as recurrence of signs and symptoms.
Safety
Safety and tolerability were assessed on the basis of the
adverse events referred or changes in vital signs, physical
examination ﬁndings, and electrocardiogram recorded before
and at the end of treatment. Laboratory safety parameters
(hematology, serum biochemistry, and urine analysis) were
assessed before and after the treatment period.
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Exercise Challenge Test
It was performed for each patient and in each visit of
evaluation.
Statistical Analysis
Chi-square test and student t test were used for signif-
icant testing.
RESULTS
A total number of 251 patients with cholinergic
urticaria were included in the study analysis. Of the total,
214 (85%) were male and 37 (15%) were female. All patients
were adolescent or adult, with age range of 16 to 29 years.
Their characteristics at the enrollment in the study are
presented in Table 1, and there are no signiﬁcant differences
among groups. Eosinophil count reduced after treatment in all
the 3 groups. Groups B and C demonstrated a reduction in
eosinophil count from the ﬁrst visit, whereas in group A, the
reduction was achieved in the second visit (Table 2). The
reduction was more in groups B and C (P , 0.01) as com-
pared with group A in their fourth visit (P , 0.05).
Itching was absent in 17.4% of patients in group A, 42.8%
in group B, and 52.4% in group C (P ¼ 0.0001). In addition,
itching decreased in 53.3% of patients in group A, 36.4% in
group B, and 30.5% in group C (P ¼ 0.006) (Table 3).
Weal was absent in 33.7% of patients in group A,
62.3% in group B, and 80.5% in group C (P ¼ 0.000). How-
ever, weal reduced in 12.2% of patients in group C, 15.6% in
group B, and 30.4 in group A (P ¼ 0.005). Both weal and
itching were absent in 30.4% of group A, in 83.1% of group
B, and in 85.4% of group C (P ¼ 0.0001).
Eosinophil count reduction was higher in group B
(96.1%) as compared with group C (85.4%) and group A
(66.3%), with highly signiﬁcant (P ¼ 0.0001) differences.
Table 4 shows the comparison between the 3 groups with
regard to the presence of signs and symptoms and eosinophil
count. The absence of signs and symptoms was demonstrated
in 55 patients (67.1%) in group C, 36 patients (44.2%) in
group B, and 3 patients (3.3%) in group A in their ﬁrst visit
(P ¼ 0.0001). In addition, eosinophil count was lower in
groups B and C than that in group A (P ¼ 0.0001), whether
the patients were with signs and symptoms or without (Table
4). However, in groups B and C, eosinophil count was higher
(6%) in group of patients with signs and symptoms than that
without (5%). In visits 2, 3, and 4 the same pattern was
demonstrated for eosinophil count.
The complete control in the ﬁrst visit was higher in
group C (67.1%) than in group B (44.2%) and group A (3.3%)
(P ¼ 0.0001). The same pattern of response to treatment was
demonstrated in other follow-up visits (Table 5). In addition,
the complete control was with high signiﬁcant differences be-
tween ﬁrst, second, third, and fourth visits for groups A and B
(P , 0.0001) and borderline signiﬁcant for group C (P ¼
0.04). This is because that response to treatment was initiated
earlier in group C as compared with groups A and B.
The frequency of relapse was higher in group A (89%)
as compared with group B (68.4%) and group C (23.5%)
(P , 0.0001) (Table 6). Adverse effects varied between the
groups (Table 7), and the variation was statistically signiﬁcant
(P , 0.0001). For group A, the most common side effect was
dry mouth (82.6%), followed by irritability (59.8%), drows-
iness (37%), and blurred vision (27.2%). In group B, the most
common side effect was weight gain (81.8%), followed by
drowsiness (74%), night mares (64.9%), dry mouth (61%),
muscle weakness (48.1%), and gastrointestinal tract distur-
bance (42.8%). In group C, the most common side effect
was gynecomastia (62.2%) and weight gain (59.7%), fol-
lowed by myalgia (47.6%), diarrhea (46.3%), and muscle
weakness (44.2%) (Table 7).
DISCUSSION
Effective therapeutic approaches for the treatment of
cholinergic urticaria are not well established. Thus, this study
was conducted as double blind but not placebo controlled to
evaluate therapeutic efﬁcacy of different treatment combina-
tion in cholinergic urticaria. The study indicated that combi-
nation used in group C was the most effective treatment
combination. However, the present study shows that complete
control was demonstrated only in 30.4% of patients (group A)
receiving 4 mg of chlorpheniramine maleate, half hour before
the exercise, plus chlordiazopoxide (5 mg) and clindium
TABLE 1. Study Population Characteristics at the Time of Entry
Variable
Group A (92) Group B (77) Group C (82)
Mean 6 SD (Average) Mean 6 SD (Average) Mean 6 SD (Average)
Age, y 21 6 5 (16–29) 23 6 4 (17–27) 23 6 3 (19–29)
WBC total count 6600 6 120 (5100–9200) 7500 6 800 (6000–9000) 7600 6 960 (5900–10,600)
Neutrophil % 61 6 5 (52–70) 60 6 6 (49–72) 63 6 6 (53–74)
Lymphocyte % 29 6 2 (21–40) 31 6 6 (19–41) 31 6 6 (19–42)
Eosinophil % 7 6 1 (5–9) 7 6 1 (5–8) 7 6 1 (5–9)
Monocyte % 2 6 1 (1–6) 2 6 1 (0–6) 1 6 1 (0–5)
Basophil % 0 (0–2) 0 (0–1) 0 (0–1)
ESR, mm/h 9.5 6 3 (4–20) 9 6 2 (6–12) 12 6 5 (4–36)
PCV % 42 6 2 (38–44) 42 6 2 (40–44) 42 6 2 (36–42)
Platelets number 172,000 6 83,900 (150,000–180,000) 170,000 6 32,400 (148,000–175,000) 165,000 6 9750 (146,000–177,000)
ESR, erythrocyte sedimentation rate; PCV, packed cell volume;
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bromide (2.5 mg) tablets, 3 times daily. However, complete
control was achieved in higher rate (83.1%) in patients (group
B) receiving 4 mg of chlorpheniramine maleate (histadine), 3
times daily, plus 25 mg of maprotiline HCl (ludiomil), once
daily at night. Furthermore, the complete control was 85.4%
in patients (group C) receiving 4 mg of chlorpheniramine
maleate (histadine) plus 200 mg of cimetidine (tagadine), 3
times daily. The differences in response rate were statistically
highly signiﬁcant between group A in one hand and groups B
and C in another hand. In addition, the difference in complete
control between groups B and C was statistically signiﬁcant.
Thus, a better therapeutic response is induced by drug com-
binations used in group C [4 mg of chlorpheniramine maleate
(histadine), 3 times daily, plus 200mg of cimetidine (tagadine),
3 times daily].
The relapse rate was higher (89%) in group of patients
receiving chlorpheniramine maleate plus chlordiazopoxide
and clindium bromide as compared with group of patients
receiving chlorpheniramine maleate plus maprotiline HCl
(68.4%) and group of patients receiving chlorpheniramine
maleate plus cimetidine (23.5%). The above differences in
relapsing rate were statistically highly signiﬁcant.
From the above ﬁndings we conclude that combination
of chlorpheniramine maleate with cimetidine was the effec-
tive treatment combination for cholinergic urticaria. This
effect may be due to combination of both H1 and H2
antagonists.
The complete control was signiﬁcantly (P , 0.0001)
different for group C (67.1%) as compared with group B
(44.2%) and group A (3.3%) in their ﬁrst visit. These ﬁndings
indicate that treatment of cholinergic urticaria with combina-
tion of H1 and H2 antagonists exerted its therapeutic effect
earlier than other combinations.
In the literature, there is only one clinical trial published
that evaluated cetirizine as treatment for cholinergic urticaria in
24 patients.20 Their study reported that cetirizine (10 or 20 mg),
for 3 weeks’ period, was satisfactory for the treatment of cho-
linergic urticaria. However, there are many successful treat-
ments of selected cases of cholinergic urticaria in literature
with different treatments. Volcheck and Li7 reported cases of
exercise-induced urticaria treated with antihistamines (H1
antagonist) only and for open period. In addition, Alexander8
used a long acting non sedating antihistamines taken 1 hour
before the exercise help in preventing exercise –induced urti-
caria and they used prednisolone as an alternative for antihis-
tamine if failed to give response.
Kaplan et al6 recommended H1 antagonist for prophy-
lactic and acute therapy for cholinergic urticaria. They used
different classes of H1 antagonist and found that
TABLE 2. Eosinophil Count at Pretreatment and Posttreatment.
Group Pretreatment Percent, Mean 6 SD
Posttreatment Percent, Mean 6 SD
PFirst Visit Second Visit Third Visit Fourth Visit
A 7 6 1 7 6 1 6 6 1 6 6 1 6 6 1 ,0.05
B 7 6 1 5 6 1 5 6 1 5 6 1 4 6 1 ,0.01
C 7 6 1 5 6 1 4 6 1 4 6 1 4 6 1 ,0.01
P .0.05 ,0.01 ,0.05 ,0.05 ,0.01
TABLE 3. Clinical Response to Treatment
Variable
Group A,
n (%)
Group B,
n (%)
Group C,
n (%) P
Itching
Increased 27 (29.3) 16 (20.8) 14 (17.1) 0.13
Decreased 49 (53.3) 28 (36.4) 25 (30.5) 0.006
Absent 16 (17.4) 33 (42.8) 43 (52.4) 0.0001
Weal
Increased 34 (36.9) 17 (22.1) 6 (7.3) 0.0001
Decreased 28 (30.4) 12 (15.6) 10 (12.2) 0.005
Absent 31 (33.7) 48 (62.3) 66 (80.5) 0.0001
Both itching and weal absent 28 (30.4) 64 (83.1) 70 (85.4) 0.0001
Eosinophil
Increased 0 (0) 0 (0) 8 (9.8) 0.002
Decreased 61 (66.3) 74 (96.1) 70 (85.4) 0.0001
Same 31 (33.7) 3 (3.9) 4 (4.8) 0.0001
TABLE 4. Comparison of Eosinophil Count in Patients With
Signs and Symptoms of Cholinergic Urticaria and Those
Without
Variable Group A Group B Group C P
First
visit
No signs and symptoms 0.0001
n (%) 3 (3.3) 34 (44.2) 55 (67.1)
Eosinophil % 7 5 5
Signs and symptoms 0.01
n (%) 89 (96.7) 43 (55.8) 27 (32.9)
Eosinophil % 7 6 6
Second
visit
No signs and symptoms 0.01
n (%) 20 (21.7) 53 (68.8) 64 (78)
Eosinophil % 5 4 4
Signs and symptoms 0.01
n (%) 72 (78.3) 24 (31.2) 18 (22)
Eosinophil % 7 6 6
Third
visit
No signs and symptoms .0.05
n (%) 25 (27.2) 60 (77.9) 65 (79.3)
Eosinophil % 4 4 4
Signs and symptoms 0.01
n (%) 67 (72.8) 17 (22.1) 17 (20.7)
Eosinophil % 6 6 5
Fourth
visit
No signs and symptoms 0.01
n (%) 28 (30.4) 64 (83.1) 70 (85.4)
Eosinophil % 4 4 3
Signs and symptoms 0.01
n (%) 64 (69.6) 13 (16.9) 12 (14.6)
Eosinophil % 6 6 5
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hydroxyzine is preferred for cholinergic urticaria. Lewis and
Erffmeger21 reported 3 cases of exercise-induced urticaria
treated with hydroxyzine with good response. Feinberg and
Toner17 reported a successful treatment of disabling cholin-
ergic urticaria with combination of cetirizine, montelukast,
and propranolol.
Beta-blockers, such as propranolol, have been reported to
be useful in cholinergic urticaria.13 Both topically applied ben-
zoyl scopolamine and oral scopolamine butylbromide may be
helpful in blocking the appearance of cholinergic urticarial
lesions after challenge14. Traditional options are antihistamines,
leukotriene inhibitors, and immunosuppressive agents.15 How-
ever, in some patients cholinergic urticaria may be refractory.
Rapid desensitization with autologous sweat has been reported
in patients resistant to conventional therapy who have sweat
hypersensitivity.16 La Shell and England11 treated a case of
severe, refractory cholinergic urticaria with danazol, with signif-
icant improvement in the control of the urticaria.
Furthermore, Metz et al18 reported successful treatment
of cholinergic urticaria with anti-IgE therapy. However,
Sabroe22 reported that omalizumab, a monoclonal IgG
anti-IgE antibody, which is successfully used in one case of
cholinergic urticaria, was not effective in control of severe
cholinergic urticaria. Although, the effectiveness of each ther-
apy mentioned above varies and does not reach the standard
agreement.23
Cholinergic urticaria has well-described, characteristic
clinical presentations, yet the precise pathological mechanism
remains incompletely understood.23 Recent reports have dem-
onstrated that subcutaneous injection of cholinergic agents
induce sweating and hives development in patients with cho-
linergic urticaria and that the symptoms of cholinergic urti-
caria are inhibited by previous atropinization of the skin24;
recent studies indicated that mast cells express muscarinic
cholinergic receptor, which is a responsible cholinergic re-
ceptor for sweating.25 In addition, acetylcholine triggers rat
mast cell degranulation.26 Thus, the above ﬁndings collected
together may suggest a role for acetylcholine in pathogenesis
of cholinergic urticaria.
Serum histamine levels are elevated in some patients
with cholinergic urticaria,3 suggesting a role for histamine in
cholinergic urticaria pathogenesis. Furthermore, treatment of
cholinergic urticaria with antihistamines is of limited success-
ful response in most cases of cholinergic urticaria. This
may suggest that histamine plays a minor role in cholinergic
urticaria pathogenesis and additional mediators may be in-
volved.3,7 Nakamizo et al23 proposed a variety of cholinergic
urticaria pathogenesis, which in turn lead to suggestion of
existence of several clinical subtypes. Thus, the presence of
these clinical subtypes may inﬂuence the response to different
types of treatment.
The limitation of this study is that the upper limit
efﬁcacy for H1 antagonists is not determined and may be
greater than 3 days. Thus, adding a fourth tablet or more
may be just as good as adding cimetidine. For example, in
cold urticaria, 4 levocetirizine tablets were better than 3, and
for cold urticaria and cholinergic urticaria, the dose of
hydroxyzine used for severe cases equaled 6 cetirizine
tablets.
In conclusion, this study indicated that combination of
H1 and H2 antagonists was more effective based on complete
control of cholinergic urticaria with lower relapsing rate.
However, a future placebo-controlled clinical trial taking
in consideration higher H1 antagonists than we used is
warranted.
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